https://explicyte.kipdev-s2.com/domain-therapeutics-and-explicyte-enter-partnership-agreement-in-immuno-oncology/ 2026-07-10T11:29:55+00:00 https://explicyte.kipdev-s2.com/explicyte-becomes-a-certified-nanostring-partner-to-advance-digital-spatial-profiling-in-oncology/ 2026-07-10T09:30:36+00:00 https://explicyte.kipdev-s2.com/wp-content/uploads/2026/07/FFPE-tissue-section-from-human-lung-cancer-GeoMx.png https://explicyte.kipdev-s2.com/wp-content/uploads/2026/07/Heatmap-view-of-the-unsupervised-clustering-of-15-ROIs-according-to-the-1800-genes-expression-profile.png https://explicyte.kipdev-s2.com/condor-consortium-awarded-rhu-funding-to-advance-precision-medicine-and-immunotherapy-in-soft-tissue-sarcomas/ 2026-07-09T15:57:02+00:00 https://explicyte.kipdev-s2.com/explicyte-and-institut-bergonie-partner-to-advance-translational-immuno-oncology-research/ 2026-07-08T16:33:20+00:00 https://explicyte.kipdev-s2.com/eurostars-grants-modify-nk-project-to-develop-a-novel-modified-nk-cell-immunotherapy-for-solid-tumours/ 2026-07-08T16:03:03+00:00 https://explicyte.kipdev-s2.com/explicyte-earns-iso-13485-and-iso-9001-certifications-for-clinical-tissue-biomarker-development-testing-in-oncology-trials/ 2026-06-10T10:27:40+00:00